ASE · Biotechnology

NNVC (NNVC) Stock

$1.54 +4.05% ASE: NNVC Healthcare

Valuation

MetricValue
Price$1.54
Market Cap$35.39M
P/E Ratio-4.43
P/B Ratio3.02
P/S Ratio0.00
EPS (TTM)$-0.35
52-Week High$2.23
52-Week Low$0.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-77.53%
ROA-44.02%
ROCE-125.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-9.0M$-8.0M$-9.0M$-9.0M$-10.0M
Net Profit$-9.0M$-8.0M$-9.0M$-8.0M$-9.0M
EPS$-0.81$-0.70$-0.74$-0.70$-0.63
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$30.0M$23.0M$17.0M$13.0M$9.0M
Total Liabilities$0$0$2.0M$1.0M$1.0M
Cash$21.0M$14.0M$8.0M$5.0M$2.0M
Borrowings$0$0$0$0$0

Latest News

NanoViricides Seeks Approval for Phase 2 Trial of NV-387 Oral Gummies to Treat Ebola in Congo MT Newswires · Jul 22, 2026 As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola ACCESS Newswire · Jul 22, 2026 NanoViricides Says Phase 2 Trial of NV-387 for Ebola Receives Ethics Approval in Congo MT Newswires · Jul 13, 2026 As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo ACCESS Newswire · Jul 13, 2026 Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily ACCESS Newswire · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-6.0M$-6.0M$-6.0M$-8.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$7.0M$-6.0M$-6.0M$-3.0M$-3.0M
Free Cash Flow$-8.0M$-6.0M$-6.0M$-6.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-26.61%
Quick Ratio3.17
Interest Coverage—
Return 1Y17.81%
Return 3Y11.69%
Return 5Y-56.23%

Ownership

Insiders Held2.61%
Institutions Held8.27%
Institutions Float Held8.49%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC511,4772026-03-31
Geode Capital Management, LLC225,3812026-03-31
UBS Group AG213,3592026-03-31
Blackrock Inc.158,7522026-03-31
Renaissance Technologies, LLC134,9002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%
IGC $0.26 +2.68% — $25.68M 0.00%
JSPR $0.63 +1.48% -0.21 $10.24M 0.00%

About NNVC

NNVC is led by CEO Anil R. Diwan, employs 7 people, headquartered in US, publicly traded since 2005.

NNVC stock trades at $1.54 with a market capitalization of $35.39M. The stock is valued at a price-to-earnings (P/E) ratio of -4.43, price-to-book of 3.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.85 and $2.23, and currently trades 30.9% below its 52-week high.

On profitability, NNVC generates a return on equity (ROE) of -77.53%, return on capital employed of -125.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides